%0 Journal Article
%T The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
%A Jianfeng Wu
%A Lixin Zhou
%A Jiyun Liu
%A Gang Ma
%A Qiuye Kou
%A Zhijie He
%A Juan Chen
%A Bin Ou-Yang
%A Minying Chen
%A Yinan Li
%A Xiaoqin Wu
%A Baochun Gu
%A Lei Chen
%A Zijun Zou
%A Xinhua Qiang
%A Yuanyuan Chen
%A Aihua Lin
%A Guanrong Zhang
%A Xiangdong Guan
%J Critical Care
%D 2013
%I BioMed Central
%R 10.1186/cc11932
%X We performed a multicenter randomized controlled trial in six tertiary, teaching hospitals in China between May 12, 2008 and Dec 22, 2010. Eligible patients admitted in ICU with severe sepsis were randomly allocated by a central randomization center to the control group or T¦Á1 group (1:1 ratio). The primary outcome was death from any cause and was assessed 28 days after enrollment. Secondary outcomes included dynamic changes of Sequential Organ Failure Assessment (SOFA) and monocyte human leukocyte antigen-DR (mHLA-DR) on day 0, 3, 7 in both groups. All analyses were done on an intention-to-treat basis.A total of 361 patients were allocated to either the control group (n = 180) or T¦Á1 (n = 181) group. The mortalities from any cause within 28 days in the T¦Á1 group and control group were 26.0% and 35.0% respectively with a marginal P value (nonstratified analysis, P = 0.062; log rank, P = 0.049); the relative risk of death in the T¦Á1 group as compared to the control group was 0.74 (95% CI 0.54 to 1.02). Greater improvement of mHLA-DR was observed in the T¦Á1 group on day 3 (mean difference in mHLA-DR changes between the two groups was 3.9%, 95% CI 0.2 to 7.6%, P = 0.037) and day 7 (mean difference in mHLA-DR changes between the two groups was 5.8%, 95% CI 1.0 to 10.5%, P = 0.017) than in the control group. No serious drug-related adverse event was recorded.The use of T¦Á1 therapy in combination with conventional medical therapies may be effective in improving clinical outcomes in a targeted population of severe sepsis.ClinicalTrials.gov NCT00711620.Severe sepsis is an important cause of admission to intensive care units (ICUs) throughout the world and is characterized by high mortality in adults [1-3]. Severe sepsis is diagnosed in more than 750,000 people annually in the United States, of whom 215,000 will die [3]. Reported mortality rates of severe sepsis ranged from 28% to 35.5% [3-7]. In spite of the adoption of therapeutic bundles based on Surviving Sepsis Campaign
%U http://ccforum.com/content/17/1/R8